Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF

Paraoxonase-1 activity in type 2 diabetes mellitus with and without nephropathy

The Egyptian Journal of Internal Medicine volume 27, pages 63–68 (2015)Cite this article

Abstract

Background

Paraoxonase-1 (PON-1) is an enzyme synthesized in the liver that has antioxidant functions as it binds to the HDL particles and prevents the oxidation of LDL, which possibly plays a role in the prevention of atherosclerosis and coronary artery disease.

Objectives

To determine PON-1 activity in type 2 diabetic patients with and without diabetic nephropathy and its correlation with the lipid profile, disease duration, and glycemic status.

Patients and methods

This study was carried out on 30 patients with type 2 diabetes mellitus who attended the diabetes and endocrine clinic at Kasr Al Ainy Hospital, Cairo University, including 20 patients with evidence of diabetic nephropathy and 10 patients without diabetic nephropathy as well as 15 healthy age-matched control participants. Fasting blood sugar, 2 h postprandial blood sugar, total cholesterol, HDL, LDL, triglycerides, and serum creatinine were measured. PON-1 activity was detected using a colorimetric method.

Results

PON-1 activity was reduced significantly in diabetic patients with and without nephropathy, with mean 226.1 ± 135.4 and 221.7 ± 119.6 nmol/ml/min, respectively, versus 758.5 ± 353.9 nmol/ ml/min in the control group (P < 0.001). PON-1 activity was not significantly different between diabetic patients with and without nephropathy. PON-1 activity was correlated negatively with HDL (r = −0.496, P = 0.026) in diabetic patients with nephropathy. PON-1 activity was not correlated significantly with disease duration and glycemic status.

Conclusion

PON-1 activity was significantly reduced in type 2 diabetes, but did not differ between diabetics with or without nephropathy.

References

  1. American diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32:S26–S67.

    Google Scholar 

  2. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40:405–412.

    Article  CAS  Google Scholar 

  3. Dihazi H, Müller GA, Lindner S, Meyer M, Asif AR, Oellerich M, Strutz F. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007; 53:1636–1645.

    Article  CAS  Google Scholar 

  4. Prabhakar S, Starnes J, Shi S, Lonis B, Tran R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007; 18:2945–2952.

    Article  CAS  Google Scholar 

  5. Ha H, Kim KH. Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C. Diabetes Res Clin Pract 1999; 45:147–151.

    Article  CAS  Google Scholar 

  6. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med (Berl) 2003; 81:766–779.

    Article  CAS  Google Scholar 

  7. Rani JA, Mythili SV. Paraoxonase 1 in type 2 diabetes mellitus – a review. Int J Pharm Sci Rev Res 2014; 28:175–179.

    Google Scholar 

  8. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54:371–392.

    Article  CAS  Google Scholar 

  9. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 2001; 21:1451–1457.

    Article  CAS  Google Scholar 

  10. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004; 39:59–66.

    Article  CAS  Google Scholar 

  11. Jenkins AJ, Best JD, Klein RL, Lyons TJ. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev 2004; 20:349–368

    Article  CAS  Google Scholar 

  12. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications, 1999

  13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.

    Article  CAS  Google Scholar 

  14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1): S1–S266.

    Google Scholar 

  15. Sampson MJ, Braschi S, Willis G, Astley SB. Paraoxonase-1 (PON1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in type II diabetes. Clin Sci (Lond) 2005; 109:189–189.

    Article  CAS  Google Scholar 

  16. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15:1812–1818.

    Article  CAS  Google Scholar 

  17. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) 2000; 98:355–363.

    Article  CAS  Google Scholar 

  18. Karabina SA, Lehner AN, Frank E, Parthasarathy S, Santanam N. Oxidative inactivation of paraoxonase – implications in diabetes mellitus and atherosclerosis. Biochim Biophys Acta 2005; 1725:213–221.

    Article  CAS  Google Scholar 

  19. Valabhji J, McColl AJ, Schachter M, Dhanjil S, Richmond W, Elkeles RS. High-density lipoprotein composition and paraoxonase activity in type I diabetes. Clin Sci (Lond) 2001; 101:659–670.

    Article  CAS  Google Scholar 

  20. Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 1711–1716.

    Article  CAS  Google Scholar 

  21. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000; 28:1708–1716.

    Article  CAS  Google Scholar 

  22. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38:163–169.

    Article  CAS  Google Scholar 

  23. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43:312–320.

    Article  CAS  Google Scholar 

  24. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 2002; 277:4301–4308.

    Article  CAS  Google Scholar 

  25. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 1998; 47:598–602.

    Article  CAS  Google Scholar 

  26. Khodeir SA, Abd El Raouf YM, Amer AE, El Fadaly NH, Abd El Latif EA. Paraoxonase gene polymorphism and activity in type 2 diabetes mellitus with microvascular complications. J Am Sci 2012; 8:27–34.

    Google Scholar 

  27. Vanitha Gowda MN, Kusuma KS, Vasudha KC. Serum paraoxonase (Arylesterase) activity in type 2 diabetes mellitus and diabetic nephropathy. Indian J Appl Res 2013; 3:351–353.

    Article  Google Scholar 

  28. Elattar N, Swelam EE, Hamed E, Elnahal A, Mostafa E. Paraoxonase 1 gene polymorphism relationship with type 2 diabetes mellitus. Life Sci J 2012; 9:1742–1751.

    Google Scholar 

  29. Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, et al. Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 2001; 50:657–660.

    Article  CAS  Google Scholar 

  30. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991; 40:277–282.

    Article  CAS  Google Scholar 

  31. Deepthi SK, G, Amar Raghu Narayan. Paraoxonase activity and its concentration in type 2 diabetes mellitus. Int J Pharm Bio Sci 2012; 3:969–973.

    CAS  Google Scholar 

  32. Patil Asmita B, Ganu Jayashree V. Paraoxonase 1, total cholesterol and HDL cholesterol in diabetes mellitus. Indian J Basic Appl Med Res 2013; 2:998–1001.

    Google Scholar 

  33. Tomas M, Latorre G, Senti M, Marrugat J. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol 2004; 57:557–569.

    Article  Google Scholar 

  34. Kural BV, Orem C, Uydu HA, Alver A, Orem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis 2004; 15:277–283.

    Article  Google Scholar 

  35. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995; 15:89–95.

    Article  CAS  Google Scholar 

  36. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002; 32:259–264.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Kasr Al Ainy Hospital, Faculty of Medicine, Cairo University, Giza, Egypt

    Nehal H. El-said, Mohammed M. Nasr-Allah & Noha A. Sadik MD

  2. Department of Clinical and Chemical Pathology, Kasr Al Ainy Hospital, Faculty of Medicine, Cairo University, Giza, Egypt

    Saher A. Sharaf

Authors
  1. Nehal H. El-said
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammed M. Nasr-Allah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noha A. Sadik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saher A. Sharaf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noha A. Sadik MD.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-said, N.H., Nasr-Allah, M.M., Sadik, N.A. et al. Paraoxonase-1 activity in type 2 diabetes mellitus with and without nephropathy. Egypt J Intern Med 27, 63–68 (2015). https://doi.org/10.4103/1110-7782.159451

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1110-7782.159451

Keywords